As the federal funding cuts to research by President Donald Trump’s administration continue to climb, University of Colorado ...

According to a McKinsey analysis, women spend 25% more time than men in poor health — and investments addressing the women’s ...

Magic mushrooms” may conjure images of people in the 1960s using hallucinogenic drugs to launch journeys of self-discovery.

Scientists discovered a new way to protect memory in Alzheimer's by targeting the blood-brain barrier instead of amyloid ...

Vivani Medical is developing GLP-1 subdermal implants that aim to provide a consistent therapeutic dose for six months, and ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Another is to find stocks with relatively affordable price tags per share. Although it's sometimes the case that the most ...

Sustainable health cannot be solved by science, clinical trial representation and access alone. It’s also down to how we live ...

Roche presented promising 96-week data from the Phase II FENopta study, showing that its investigational drug, fenebrutinib, significantly reduce ...

Angelini is paying $50 million upfront for ex-North American rights to radiprodil, with another $520 million in the offing in ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...